



## Genocea to Participate in the B. Riley Securities' Virtual Oncology Investor Conference

January 19, 2021

CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- [Genocea Biosciences, Inc.](http://www.genocea.com) (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, president and chief executive officer, will participate in a fireside chat at B. Riley Securities' Virtual Oncology Investor Conference on January 21, 2021 from 11:00 am – 11:30 am Eastern Time. A live webcast of the fireside chat will be available on the Genocea website at <http://ir.genocea.com>. This event will also remain archived on the Genocea website for approximately 90 days.

### **About Genocea Biosciences, Inc.**

Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens, Inhibigens™, that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood. To learn more, please visit [www.genocea.com](http://www.genocea.com).

### **Investor Contact:**

Dan Ferry  
617-430-7576  
[daniel@lifesciadvisors.com](mailto:daniel@lifesciadvisors.com)



Source: Genocea Biosciences, Inc.